National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Delstrigo® is indicated for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine or tenofovir



NCPE Assessment Process Complete
Rapid review commissioned 06/12/2018
Rapid review completed 16/01/2019
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that Destrigo® be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013